Marco Purbhoo is a Non-Clinical Lecturer in Hepatology within the Department of Medicine at Imperial College London.
Dr Purbhoo obtained his undergraduate degree in Biochemistry and his D. Phil. in Clinical Medicine from the University of Oxford. Dr Purbhoo undertook post-doctoral work at the Howard Hughes Medical Institute at Stanford University where he investigated the molecular processes underlying T cell activation and antigen recognition, using advanced fluorescence imaging techniques. He continued to specialize in the application of imaging techniques to investigate novel molecular processes in T cells and NK cells during a subsequent post-doctoral position at Imperial College.
Dr Purbhoo was appointed Lecturer in the Department of Medicine in September 2008. His research in molecular immunology focuses on the role of inhibitory receptors in regulating immune responses to viral infection as well as in the immuno-oncology of hepatocellular carcinoma.
Dr Purbhoo has lectured on the BSc courses in Biology and Biomedical Sciences, the MSc on the Molecular Biology and Pathology of Viruses, and has acted as Immunology-module lead for the BSc in Gastroenterology and Hepatology. Dr Purbhoo is Fellow of the Higher Education Acadamy.
Dr Purbhoo's research is funded by the Wellcome Trust.
et al., 2017, KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C, Science Immunology, Vol:2, ISSN:2470-9468
et al., 2017, STAT4-associated natural killer cell tolerance following liver transplantation, Gut, Vol:66, ISSN:0017-5749, Pages:352-+
et al., 2016, Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications, Cytotherapy, Vol:18, ISSN:1465-3249, Pages:1209-1218
et al., 2016, easySTORM: a robust, lower-cost approach to localisation and TIRF microscopy, Journal of Biophotonics, Vol:9, ISSN:1864-0648, Pages:948-957
et al., 2016, Is differential T cell receptor patterning at the immune synapse mediated by glycosylation of the viral ligand UL18 and the inhibitory receptor ILT2?, Spring Meeting on Clinician Scientists in Training, ELSEVIER SCIENCE INC, Pages:18-18, ISSN:0140-6736